In summary, our data indicate that JPYS can correct CKD anemia through induction of EPO production and regulation of iron metabolic targets and the mechanism of which involves in the translational control of HIF-2α protein accumulation via ERK signaling. This evidence concerns the gene EPAS1 and chronic kidney disease.